BridgeBio Pharma

Metallic arrow symbols illuminated by blue and magenta lights forming a graph on blue and magenta background
Biotech

BridgeBio's muscle weakness data impress ahead of FDA filing

BridgeBio took another step toward the approval of its muscle weakness candidate, reporting phase 3 efficacy data that analysts called impressive.
Nick Paul Taylor Mar 12, 2026 10:30am
business targets illustration

BridgeBio preps approval push for dwarfism drug after ph. 3 win

Feb 12, 2026 7:30am
winnter trophy star

BridgeBio's calcium deficiency candidate scores phase 3 win

Oct 29, 2025 7:00am
hurdles

BridgeBio aces phase 3 rare disease test, clearing path to FDA

Oct 27, 2025 7:00am
SPAC special purpose acquisition company

BridgeBio's cancer spinout backs SPAC as path to Nasdaq

Feb 28, 2025 9:25am
scissors cutting the word budget in half

BridgeBio cuts gene therapy budget as clinical data disappoint

Sep 11, 2024 7:50am